July 2, 2007 - Analysis of the minimally invasive vertebral compression fracture (VCF) treatment market by Millennium Research Group (MRG) reveals that the U.S. market is expected to grow at double-digit rates over the next five years. This expected growth is due in part to the popularity of kyphoplasty and the emergence of new devices and competitors in the vertebroplasty market. Both kyphoplasty and vertebroplasty are minimally invasive, nonsurgical procedures, which involve the insertion of a special bone needle through the posterior soft tissues and the injection of a small amount of orthopedic cement through the needle into the vertebral body in order to relieve the pain caused by vertebral compression fractures.
"Currently, Kyphon is the largest player in the minimally invasive VCF treatment market with its kyphoplasty products. However, all the competitors including Kyphon, Stryker, ArthroCare, Cardinal Health, and Cook continue to improve the safety, efficacy, and ease-of-use of their vertebroplasty products," said Kevin Flewwelling, Senior Analyst at MRG. "Furthermore, newer competitors like Medtronic Spinal and Biologics, Spine Wave, and Spineology are providing practitioners new treatment alternatives to choose from."
For more information: www.mrg.net